title: Successful treatment of small-cell lung cancer with irinotecan in a hemodialysis patient with end-stage renal disease.
abstract: The prognosis of patients with end-stage renal disease has improved with advances in hemodialysis techniques. However, many patients who undergo hemodialysis suffer from various types of cancer. Limited data is available to guide clinical management of these patients who may have impaired renal function. Here, we report our experience with the use of irinotecan for the treatment of a hemodialysis patient with small-cell lung cancer and end-stage renal disease.
authors.affiliation: Department of Internal Medicine, College of Medicine, Chosun University, Gwangju, Korea.
authors.forename: Dong Min
authors.initials: DM
authors.lastname: Kim
authors.forename: Hyun Lee
authors.initials: HL
authors.lastname: Kim
authors.forename: Choon Hae
authors.initials: CH
authors.lastname: Chung
authors.forename: Chi Young
authors.initials: CY
authors.lastname: Park
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D000077146:Irinotecan; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000379:methods*; D055752:Small Cell Lung Carcinoma / Q000150:complications / Q000188:drug therapy*; D059004:Topoisomerase I Inhibitors
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D002166:Camptothecin